Usefulness of laboratory data in estimation of Crohn's disease activity

Nadza Zubcevic1, Rusmir Mesihovic, Smail Zubcevic

  • 1Gastroenterohepatology Clinic, Clinical Centre of University in Sarajevo, Bosnia and Herzegovina.

Medicinski Arhiv
|April 29, 2010
PubMed

Insights

C-reactive protein (CRP) and platelet count are reliable indicators for assessing Crohn's disease activity. However, no single lab test can definitively distinguish between moderately severe and severe disease stages.

Area of Science:

  • Gastroenterology
  • Clinical Medicine
  • Inflammatory Bowel Disease Research

Background:

  • Crohn's disease (CD) is a chronic inflammatory condition with a variable and severe course.
  • Clinicians commonly use laboratory markers like erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), leukocyte count (Le), and platelet count to gauge disease activity.
  • Accurate assessment of CD activity is crucial for effective patient management.

Purpose of the Study:

  • To evaluate the diagnostic value of various laboratory parameters in assessing the severity of Crohn's disease.
  • To identify the most reliable laboratory indicators for monitoring CD activity.
  • To determine if specific laboratory markers can differentiate between disease severity levels.

Main Methods:

  • A study involving 36 patients (15 male, 21 female) diagnosed with Crohn's disease.
  • Patients were categorized into mild (MD), moderately severe (MSD), and severe (SD) disease groups based on the Crohn's Disease Activity Index (CDAI).
  • Statistical analysis using 95% Confidence Interval (CI) tests was performed to assess the association between laboratory parameters and disease severity.

Main Results:

  • C-reactive protein (CRP) demonstrated statistical significance in differentiating mild from moderately severe (95% CI 6.645-74.333) and mild from severe disease (95% CI 4.114-135.278).
  • Mean platelet volume (MPV) was significant only between mild and moderately severe disease (95% CI 0.060-2.909).
  • Hemoglobin, hematocrit, and platelet count showed significance between mild and moderately severe, and mild and severe disease groups. Leukocyte count did not correlate significantly with disease activity.

Conclusions:

  • CRP, MPV, hemoglobin, hematocrit, and platelet count emerged as the most reliable laboratory indicators for Crohn's disease activity in this cohort.
  • Leukocyte count was not found to be a significant indicator of disease activity.
  • No single laboratory parameter effectively distinguished between moderately severe and severe Crohn's disease, highlighting the need for combined assessments.

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...